Sign in to view content

Economic Benefit of Higher Durability Anti-VEGF Agents in the Treatment of Neovascular Macular Degeneration

Sabin Dang, MD

Video
Published 2023

Related

Prophylaxis Intravitreal Aflibercept Against Conversion to Neovascular Age-Related Macular Degeneration in High Risk Eyes
Jeffrey S. Heier, MD
Updates from the Field
2019
Intravitreal Gene Therapy for Diabetic Macular Edema With ADVM-022: First-Time Data Presentation of Prospective, Randomized Phase 2 INFINITY Trial
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2021
Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results
Peter J. Kertes, MD, FRCS(C)
Annual Meeting Talks
2020

Category: Socioeconomics

See more